SPRY
ARS Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
3.38
close · 2026-10-30
value
44
cheaper than peers44
quality
19
stronger fundamentals19
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 1 year ago | 3.9% | 91 |
| earnings yield, 1 year ago | 2.4% | 88 |
| price to sales | 2.87× | 82 |
| earnings yield, 2 years ago | -16.9% | 49 |
| earnings yield, 3 years ago | -25.7% | 41 |
| cash flow yield, 3 years ago | -12.0% | 40 |
| cash flow yield, 2 years ago | -17.7% | 34 |
| earnings yield, latest year | -51.5% | 21 |
| cash flow yield, latest year | -50.9% | 18 |
| price to book | 26.83× | 6 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 114.2% | 79 |
| operating margin | -182.6% | 47 |
| return on equity | -210.3% | 11 |
| debt to equity | 1371.5% | 3 |
4 of 4 measures available
Facts
| market cap | $336M |
| free cash flow | -$117.7M |
| employees | 195 |
| first trade | 2020-12-04 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-09-02 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.74 | 0.08 | -0.57 | -0.87 |
| free cash flow | -$171.2M | $13.0M | -$59.4M | -$40.3M |
| net income | -$171.3M | $8.0M | -$54.4M | -$34.7M |
| revenue | $84.3M | $89.1M | $30,000 | $1.3M |
| unusual items | not reported | not reported | not reported | -$140,000 |